Initial 4-Year Experience With Microaxial Flow Pumps Within a Tertiary Centre in Regional Australia
Heart, Lung and Circulation · 2026
DOI: 10.1016/j.hlc.2026.02.017 ↗Kurz gefasst
Fachartikel in der Zeitschrift Heart, Lung and Circulation, 2026. Verfasst von Thomas Quirk und 7 weiteren Autor:innen. Beteiligte Einrichtung: John Hunter Hospital Newcastle, NSW, Australia. Electronic address: thomas.quirk@health.nsw.gov.au. Hauptthemen laut MEDLINE: Shock, Cardiogenic, Heart-Assist Devices, Tertiary Care Centers, Percutaneous Coronary Intervention. Die Arbeit nennt 13 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND & AIM: The Microaxial Flow Pump (MFP) is a miniaturised rotary pump that aspirates blood from the left ventricle and expels it into the ascending aorta. It unloads the left ventricle and increases mean arterial pressure and cardiac output. MFP is most commonly utilised in cardiogenic shock, for protected percutaneous coronary intervention (PCI), and for ventricular offloading in veno-arterial extracorporeal membrane oxygenation (VA-ECMO). METHOD: We conducted a retrospective review of all patients who underwent MFP insertion at John Hunter Hospital, Australia. Categorical data are represented as counts and percentages, with continuous variables described as means with standard deviations. RESULTS: Twenty-three MFP devices were inserted between September 2020 and May 2024. Five (22%) were for protected PCI, three (13%) for venting with VA-ECMO (ECPELLA), and 15 (65%) for acute coronary syndrome (ACS) and cardiogenic shock. The median age for the overall cohort was 62 years, with a 74% male predominance. Eighty percent of the protected PCI cohort were elective outpatient procedures, and there were no deaths in this cohort. The mortality in the ECPELLA group was 67%. Thirteen (87%) of the patients with cardiogenic shock presented with an anterior infarct, and 53% had cardiac arrest on admission. The overall morality in the cardiogenic shock cohort was 40%. Complications in this cohort included limb ischaemia in four patients (17%) and site bleeding in seven patients (30%). Four patients (17%) required vascular surgery intervention. CONCLUSION: Our initial experience showed the use of MFP in a tertiary centre was safe and feasible, allowing progression from protected percutaneous intervention to acute cardiogenic shock.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- John Hunter Hospital Newcastle, NSW, Australia. Electronic address: thomas.quirk@health.nsw.gov.au.
- John Hunter Hospital Newcastle, NSW, Australia.
- John Hunter Hospital Newcastle, NSW, Australia; The University of Newcastle, Newcastle, NSW, Australia.
Zitieren
APA
Quirk, T., Sritharan, S., Short, K., McLean, L., Khan, A., Collins, N., Boyle, A., & Al-Omary, M. (2026). Initial 4-Year Experience With Microaxial Flow Pumps Within a Tertiary Centre in Regional Australia. Heart, Lung and Circulation. https://doi.org/10.1016/j.hlc.2026.02.017
Vancouver
Quirk T, Sritharan S, Short K, McLean L, Khan A, Collins N, et al. Initial 4-Year Experience With Microaxial Flow Pumps Within a Tertiary Centre in Regional Australia. Heart, Lung and Circulation. 2026. doi:10.1016/j.hlc.2026.02.017
BibTeX
@article{Quirk2026,
author = {Quirk, Thomas and Sritharan, Shanathan and Short, Kaylea and McLean, Lewis and Khan, Arshad and Collins, Nicholas and Boyle, Andrew and Al-Omary, Mohammad},
title = {Initial 4-Year Experience With Microaxial Flow Pumps Within a Tertiary Centre in Regional Australia},
journal = {Heart, Lung and Circulation},
year = {2026},
doi = {10.1016/j.hlc.2026.02.017}
}
EUVIMED